ClinicalTrials.gg
RecruitingNCT06334302Updated Apr 12, 2024

The Effect of Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread" With 80% Reduced Sucrose on Glucose Response of People With TID

An interventional study of Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread" and Active Control-Nutella hazelnut cocoa spread in Type1diabetes, sponsored by Rabin Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Rabin Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.

Planned enrollment
18th of 38
30 · median 30
Started
2024
with 2 others
No phase
31 of 42
5 open now
Registered
38th of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the 18th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 31 with no phase, and was the 38th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, or all of them as a file.
02

Study summary

Omega Galil has developed a novel fatty sweetener that allows the use of up to 80% less sugar (particularly sucrose) and yet achieves a natural sweet flavor, using a novel technology of milling the natural sucrose crystals together with oil and thus creating a micro-suspension of sugar in oil or fat. The suspension increases the surface area of the sugar particles and thus a lower quantity of sugar is required in order to reach an enhanced perception of sweetness at the sweet taste receptors in the mouth. Omega Galil provides fatty food products that use up to 80% less sucrose, while tasting as sweet as regular sugar sweetened foods, with no aftertastes of sugar substitutes, and no chemical modifications or additives.

Postprandial glucose (PPG) excursions in Type 1 Diabetes happen mainly due to a delay in subcutaneous insulin absorption and action, but also among other factors, depend on the meal composition. The glycemic index (GI) ranks foods based on acute glycemic response over a 2-h period of 50 g of available carbohydrates (CHO) of a test food compared with the reference standard glucose. Glycemic Load (GL) is a GI-weighted measure of carbohydrate content, which estimates the impact of carbohydrate intake using the GI while taking into account the amount of carbohydrates that are eaten in a serving. Several studies have demonstrated differences in PPG after consumption of low versus high GI meals, with rapid glucose spikes following high GI meals . Helping people with T1D achieve a diet with a lower glycemic load can improve both their quality of life and their diabetes-associated complications.

The proposed randomized, double blind, cross-over, active control, clinical trial aims to:

  1. compare the glycemic response of T1D subjects to 20 grams of the O'Sweet sugar-reduced spread containing 8% sugar and a total of 1.6 grams of sucrose per meal, with their glycemic response to 20 grams of control Nutella spread, containing 56% sugar and a total of 11 grams sucrose per meal.
  2. compare the acceptance ("Not sweet enough, just right or too sweet") Labeled Magnitude score of O'Sweet compared to the control spread (Nutella).
03

Conditions studied

  • Type1diabetes
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T1D patients with diabetes duration >1 year
  • 18-35 years of age
  • Normal weight ( 20- 30 kg/m2)
  • Non-smoker
  • \<9%
  • Patient treated with Continuous Glucose Monitoring system (CGM's)

Exclusion criteria

Exclusion Criteria:

  • Acute Upper Respiratory Tract Infection (URTI) within 2 weeks of enrollment
  • A gastro-intestinal condition that could disrupt intestinal absorption or motility, and thereby impair postprandial glucose absorption (e.g. diabetic gastroparesis, celiac disease, or malabsorption).
  • A chronic illness in the past 5 years, including among others inflammatory, metabolic, neoplastic, and congenital disease.
  • Use of medications other than insulin (e.g. Antibiotics/antifungal, analgesics) during the study and 2 weeks before enrollment;
  • Neuro-psychiatric disorders
  • Known food allergies or intolerances
  • Self-reported sinus, taste or smell dysfunction
  • Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Omega Galil O'Sweet hazelnut cocoa spread

    Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults

    Other: Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread"

  • Active comparator
    Nutella hazelnut cocoa spread

    Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4

    Other: Active Control-Nutella hazelnut cocoa spread

Interventions

  • OtherOmega Galil Hazelnut Chocolate Spread "O'Sweet Spread"

    Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults

    Also known as: "O'Sweet Spread"

  • OtherActive Control-Nutella hazelnut cocoa spread

    Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4

    Also known as: Nutella hazelnut cocoa spread

06

What researchers measure

Primary outcomes

  1. Delta postprandial glucose level

    The difference between pre-meal and peak postprandial glucose level in each of the two 2 hours' meal tests.

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

Secondary outcomes

  1. Incremental area under the curve (iAUC)

    Incremental area under the curve (iAUC) using continuous glucose sensor data \> 180 mg/dl between the beginning of the meal and 2 hours postprandial (defined as the postprandial period).

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  2. Peak postprandial glucose level

    The peak postprandial glucose level during the 2-hour postprandial period

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  3. Time in range (TIR) of 70-180 mg/dl

    Time in range (TIR) of 70-180 mg/dl during the postprandial period

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  4. Percentage of subjects who reached the desired glucose target

    The percentage of subjects who reached the desired glucose target (70-180 mg/dl) during the postprandial period (70% of the time)

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  5. The percentage of time spent above 180 mg/dl

    The percentage of time spent above 180 mg/dl

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  6. The percentage of time spent above 250 mg/dl

    The percentage of time spent above 250 mg/dl

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  7. The percentage of time spent above 350 md/dl

    The percentage of time spent above 350 md/dl

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

  8. Labeled Magnitude Scale (gLMS)

    Acceptance of the sweetness level Labeled Magnitude Scale (gLMS)

    Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Apr 2024, 1 month after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 1 month is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 28, 2024
StartActual
Mar 25, 2024
Primary completionEst.
Apr 25, 2024
CompletionEst.
Apr 25, 2024
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06334302
Collaborators
Omega 3 Galilee
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Mar 25, 2024
Primary completion
Apr 25, 2024 (estimated)
Completion
Apr 25, 2024 (estimated)
Last update
Apr 12, 2024

Study contacts

Alona Hamou, Msc
Contact
alonah@clalit.org.il
972-3-9253778
Michal Gavan, PHd
principal investigator · Schneider Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion